标题
Therapeutic drug monitoring of 5-fluorouracil
作者
关键词
Capecitabine, Body Surface Area, Dose Adjustment, Therapeutic Drug Monitoring, mCRC Patient
出版物
CANCER CHEMOTHERAPY AND PHARMACOLOGY
Volume 78, Issue 3, Pages 447-464
出版商
Springer Nature
发表日期
2016-05-24
DOI
10.1007/s00280-016-3054-2
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Safety, pharmacokinetics (PK), and cost-effectiveness of upfront genotyping of DPYD in fluoropyrimidine therapy.
- (2017) M. J. Deenen et al. JOURNAL OF CLINICAL ONCOLOGY
- Updated survival from a randomized phase III trial (MPACT) of nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients (pts) with metastatic adenocarcinoma of the pancreas.
- (2017) David Goldstein et al. JOURNAL OF CLINICAL ONCOLOGY
- Evaluation of an oral uracil loading test to identify DPD-deficient patients using a limited sampling strategy
- (2016) Maurice C. van Staveren et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Volasertib Versus Chemotherapy in Platinum-Resistant or -Refractory Ovarian Cancer: A Randomized Phase II Groupe des Investigateurs Nationaux pour l'Etude des Cancers de l'Ovaire Study
- (2016) Eric Pujade-Lauraine et al. JOURNAL OF CLINICAL ONCOLOGY
- Upfront Genotyping ofDPYD*2Ato Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis
- (2016) Maarten J. Deenen et al. JOURNAL OF CLINICAL ONCOLOGY
- The optimization of 5-fluorouracil (5FU) dose by pharmacokinetic (PK) monitoring in Asian patients with advanced-stage gastrointestinal (GI) cancer.
- (2015) I Peng Thomas Soh et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumor reduction in pancreatic versus metastatic sites in a randomized phase III study (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem alone.
- (2015) Volker Kunzmann et al. JOURNAL OF CLINICAL ONCOLOGY
- Deciphering the Role of Phosphatidylinositol 3-Kinase Mutations in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
- (2015) Shom Goel et al. JOURNAL OF CLINICAL ONCOLOGY
- TranslatingDPYDgenotype into DPD phenotype: using theDPYDgene activity score
- (2015) Linda M Henricks et al. PHARMACOGENOMICS
- Cost Effectiveness Analysis of Pharmacokinetically-Guided 5-Fluorouracil in FOLFOX Chemotherapy for Metastatic Colorectal Cancer
- (2014) Daniel A. Goldstein et al. Clinical Colorectal Cancer
- Therapeutic drug monitoring in cancer – Are we missing a trick?
- (2014) Christophe Bardin et al. EUROPEAN JOURNAL OF CANCER
- Human uridine phosphorylase-1 inhibitors: a new approach to ameliorate 5-fluorouracil-induced intestinal mucositis
- (2014) Daiana Renck et al. INVESTIGATIONAL NEW DRUGS
- Predicting 5-fluorouracil toxicity: DPD genotype and 5,6-dihydrouracil:uracil ratio
- (2014) Johanna Sistonen et al. PHARMACOGENOMICS
- Personalized Dosing via Pharmacokinetic Monitoring of 5-Fluorouracil Might Reduce Toxicity in Early- or Late-Stage Colorectal Cancer Patients Treated With Infusional 5–Fluorouracil-Based Chemotherapy Regimens
- (2013) Christina Leah B. Kline et al. Clinical Colorectal Cancer
- Pharmacokinetically Guided Dose Adjustment of 5-FU—A Critical Element Toward Personalized Medicine
- (2013) Gaurav Goel et al. Clinical Colorectal Cancer
- Without Therapeutic Drug Monitoring, There Is No Personalized Cancer Care
- (2013) J H Beumer CLINICAL PHARMACOLOGY & THERAPEUTICS
- Clinical Pharmacogenetics Implementation Consortium Guidelines for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing
- (2013) K E Caudle et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Evaluation of 5-fluorouracil pharmacokinetic models and therapeutic drug monitoring in cancer patients
- (2013) André BP van Kuilenburg et al. PHARMACOGENOMICS
- Evaluation of predictive tests for screening for dihydropyrimidine dehydrogenase deficiency
- (2013) M C van Staveren et al. PHARMACOGENOMICS JOURNAL
- Cost-Effectiveness Of Pharmacokinetic Dosing Of 5-Fluorouracil In Metastatic Colorectal Cancer In The United Kingdom
- (2013) R. Becker et al. VALUE IN HEALTH
- Individual Fluorouracil Dose Adjustment in FOLFOX Based on Pharmacokinetic Follow-Up Compared With Conventional Body-Area-Surface Dosing: A Phase II, Proof-of-Concept Study
- (2012) Olivier Capitain et al. Clinical Colorectal Cancer
- Body-Surface Area–Based Chemotherapy Dosing: Appropriate in the 21st Century?
- (2012) Jan H. Beumer et al. JOURNAL OF CLINICAL ONCOLOGY
- Modeling the 5-Fluorouracil Area Under the Curve Versus Dose Relationship to Develop a Pharmacokinetic Dosing Algorithm for Colorectal Cancer Patients Receiving FOLFOX6
- (2012) R. R. Kaldate et al. ONCOLOGIST
- Preliminary observations indicate variable patterns of plasma 5-fluorouracil (5-FU) levels during dose optimization of infusional 5-FU in colorectal cancer patients
- (2011) Christina Leah Kline et al. CANCER BIOLOGY & THERAPY
- Body Surface Area–based Dosing of 5-Fluoruracil Results in Extensive Interindividual Variability in 5-Fluorouracil Exposure in Colorectal Cancer Patients on FOLFOX Regimens
- (2011) Jennifer Saam et al. Clinical Colorectal Cancer
- Differential Expression of Uridine Phosphorylase in Tumors Contributes to an Improved Fluoropyrimidine Therapeutic Activity
- (2011) D. Cao et al. MOLECULAR CANCER THERAPEUTICS
- A review of analytical methods for the determination of 5-fluorouracil in biological matrices
- (2010) Massimo Breda et al. ANALYTICAL AND BIOANALYTICAL CHEMISTRY
- Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer
- (2010) Michel Ducreux et al. INTERNATIONAL JOURNAL OF CANCER
- Costs associated with complications are lower with capecitabine than with 5-fluorouracil in patients with colorectal cancer
- (2009) Edward Chu et al. CANCER
- Pharmacokinetically Guided Dose Adjustment of 5-Fluorouracil: A Rational Approach to Improving Therapeutic Outcomes
- (2009) M. Wasif Saif et al. JNCI-Journal of the National Cancer Institute
- Costs Associated with Capecitabine or 5-Fluorouracil Monotherapy after Surgical Resection in Patients with Colorectal Cancer
- (2009) Edward Chu et al. ONCOLOGY
- Cost-Effectiveness Analysis of Capecitabine Compared with Bolus 5-Fluorouracil/l-Leucovorin for the Adjuvant Treatment of Colon Cancer in Japan
- (2009) Takeru Shiroiwa et al. PHARMACOECONOMICS
- 13C-5-FU breath test current status and future directions: a comprehensive review
- (2009) Hany H Ezzeldin et al. Journal of Breath Research
- Pharmacoeconomic Benefits of Capecitabine-Based Chemotherapy in Metastatic Colorectal Cancer
- (2008) Edward Chu et al. JOURNAL OF CLINICAL ONCOLOGY
- Individual Fluorouracil Dose Adjustment Based on Pharmacokinetic Follow-Up Compared With Conventional Dosage: Results of a Multicenter Randomized Trial of Patients With Metastatic Colorectal Cancer
- (2008) Erick Gamelin et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started